
    
      Twenty-eight subjects will be recruited and entered into one of three dose groups 1mg/kg,
      5mg/kg, 10mg/kg or placebo. Subjects will be stagger dosed into one of the three groups and
      randomly assigned to receive Valortim or saline. Subjects will reside in the clinical trial
      Phase I Unit from Day -1 through Day 2. After discharge on Day 2, all subjects will return to
      the Phase I unit 7 times at specified time points over an additional 130 days post-dosing
      (133 days total participation from check-in on Day -1)or placebo.
    
  